Impact of switching to second-generation antipsychotics on the treatment of long-term inpatients with schizophrenia

被引：0
|
作者：
Yamawaki, Y. [1 ]
Yoshino, A. [2 ]
Sawa, M. [2 ]
Jin-nin, R. [3 ]
Tamai, K. [2 ]
Adachi, T. [2 ]
Yukutake, E. [2 ]
Toki, S. [3 ]
Oyamada, T. [2 ]
Takahashi, T. [2 ]
Akagi, H. [4 ]
机构：
[1] Hiroshima Int Univ, Hiroshima, Japan
[2] Mihara Hosp, Kyoto, Japan
[3] Hiroshima Univ, Dept Psychiat, Hiroshima 730, Japan
[4] Hiroshima Int Univ, Dept Pharm, Kure, Japan
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2012年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-01-068
引用
收藏
页码：65 / 65
页数：1
相关论文
共 50 条
  • [31] Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia
    Jaffe, AB
    Levine, J
    JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 : 3 - 6
  • [32] Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia
    McCue, Robert E.
    Waheed, Rubina
    Urcuyo, Leonel
    Orendain, Geraldine
    Joseph, Michel D.
    Charles, Richard
    Hasan, Syed M.
    BRITISH JOURNAL OF PSYCHIATRY, 2006, 189 : 433 - 440
  • [33] Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications
    Gentile, S.
    OBESITY REVIEWS, 2009, 10 (05) : 527 - 542
  • [34] Effectiveness of second-generation antipsychotics with acute-phase schizophrenia
    Hatta, Kotaro
    Sato, Koji
    Hamakawa, Hiroshi
    Takebayashi, Hiroshi
    Kimura, Naoto
    Ochi, Shinichiro
    Sudo, Yasuhiko
    Asukai, Nozomu
    Nakamura, Hiroyuki
    Usui, Chie
    Kawabata, Toshitaka
    Hirata, Toyoaki
    Sawa, Yutaka
    SCHIZOPHRENIA RESEARCH, 2009, 113 (01) : 49 - 55
  • [35] The use of second-generation antipsychotics in the public sector: Switching patterns and combined antipsychotic treatment
    Love, RC
    Kelly, DL
    Kreyenbuhl, JA
    Conley, RR
    SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 274 - 274
  • [36] Long-term treatment with long acting injecatble risperidone and oral second generation antipsychotics in patients with schizophrenia (LARA): An interim-analysis
    Ibach, B.
    Schreiner, A.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 157 - 157
  • [37] Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia
    Resnick, Sandra G.
    Rosenheck, Robert A.
    Canive, Jose M.
    De Souza, Cyril
    Stroup, T. Scott
    McEvoy, Joseph
    Davis, Sonia
    Keefe, Richard S. E.
    Swartz, Marvin
    Lieberman, Jeffrey
    JOURNAL OF BEHAVIORAL HEALTH SERVICES & RESEARCH, 2008, 35 (02): : 215 - 225
  • [38] Employment Outcomes in a Randomized Trial of Second-Generation Antipsychotics and Perphenazine in the Treatment of Individuals with Schizophrenia
    Sandra G. Resnick
    Robert A. Rosenheck
    Jose M. Canive
    Cyril De Souza
    T. Scott Stroup
    Joseph McEvoy
    Sonia Davis
    Richard SE Keefe
    Marvin Swartz
    Jeffrey Lieberman
    The Journal of Behavioral Health Services & Research, 2008, 35 : 215 - 225
  • [39] Acylcarnitine levels in paranoid schizophrenia with metabolic syndrome during treatment of second-generation antipsychotics
    Mednova, I.
    Chernonosov, A.
    Kornetova, E.
    Koval, V.
    Ivanova, S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S313 - S313
  • [40] Understanding and managing cardiac side-effects of second-generation antipsychotics in the treatment of schizophrenia
    Sweeney, Mark
    Whiskey, Eromona
    Patel, Rishi K.
    Tracy, Derek K.
    Shergill, Sukhi S.
    Plymen, Carla M.
    BJPSYCH ADVANCES, 2020, 26 (01) : 26 - 40
12345